PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis StudyZacks Investment Research • 03/11/25
Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks OutInvestors Business Daily • 03/10/25
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia VeraBusiness Wire • 03/03/25
Protagonist Therapeutics (PTGX) Tops Q4 Earnings and Revenue EstimatesZacks Investment Research • 02/21/25
Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateAccesswire • 02/21/25
Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025Accesswire • 12/19/24
Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024Accesswire • 11/22/24
Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development CandidateAccesswire • 11/19/24
Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 11/13/24
Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/07/24
Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateAccesswire • 11/07/24
Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH MeetingAccesswire • 11/05/24
Protagonist Therapeutics (PTGX) is on the Move, Here's Why the Trend Could be SustainableZacks Investment Research • 10/15/24
Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst OpinesBenzinga • 09/10/24
Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024Accesswire • 09/03/24
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/06/24
Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAccesswire • 08/06/24
Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific AdvisorAccesswire • 07/31/24
Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024Accesswire • 07/22/24